Loading...
•
Sep 30, 2021
Wave Life Sciences Q3 2021 Earnings Report
Wave Life Sciences announced Q3 2021 financial results and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $6.2 million for the third quarter of 2021, with revenue of $36.4 million. The company highlighted advancements in its RNA editing capabilities and the initiation of dosing in three clinical trials.
Strengthened balance sheet with approximately $52 million.
Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic threshold.
Dosing ongoing in three clinical programs (WVE-004, WVE-003, WVE-N531); data being generated through 2022 to enable decision-making.
Wave expects to share additional ADAR editing data using AIMers in scientific publications and presentations in 2022.
Forward Guidance
Wave expects that its existing cash and cash equivalents will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...